Solventum Corporation (SOLV), with a market capitalization of approximately $14.5 billion, is a global healthcare company that develops solutions using health, material, and data science. The Eagan, Minnesota-based company’s technologies help healthcare professionals improve patient outcomes, enhance efficiency, and deliver better, smarter, safer care.
Shares of this leading healthcare company have slightly underperformed the broader market over the past year. SOLV has gained 16.2% over this period, while the broader S&P 500 Index ($SPX) has rallied 20.6%. On a year-to-date basis, SOLV has also underperformed, gaining 9.1% compared with the index’s 13.9% gain over the same period.
Narrowing the comparison, SOLV has also underperformed the First Trust Health Care AlphaDEX Fund (FXH), which has climbed 25.4% over the past year and gained 15.5% on a YTD basis.
On August 5, Solventum reported its Q2 FY2026 earnings, with shares moving down marginally. Net sales grew 2.2% year over year to $2.21 billion, while organic sales increased 9.5%, reflecting strong performance across all reportable segments. Adjusted EPS rose 50.9% to $2.55 from the prior year’s quarter.
Solventum raised its full-year outlook, increasing organic sales growth guidance to 2.50%-3%. The company also lifted its adjusted EPS guidance to $7.10-$7.20, up from the prior $6.40-$6.60 range, while raising its free cash flow outlook to $200 million-$300 million, up from approximately $200 million previously.
For the current fiscal year ending in December 2026, analysts expect SOLV’s diluted EPS to rise 18.2% to $7.22. SOLV has surpassed consensus EPS estimates in each of the past four quarters, which is impressive.
Among the 16 analysts covering SOLV stock, the consensus rating is a “Moderate Buy.” The rating is based on eight “Strong Buys,” six “Holds,” and two “Strong Sells.”
SOLV’s analyst configuration is more bullish than it was a month ago, when the stock had seven “Strong Buy” recommendations.
On August 6, Wells Fargo analyst Nathan Treybeck maintained a “Hold” rating on Solventum Corporation and set an $89 price target.
The mean price target of $93.13 implies a 7.7% upside from SOLV’s current share price, while the Street-high target of $113 suggests a potential upside of 30.7%.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/The%20sign%20for%20Marvell%20Technology%20out%20front%20of%20a%20corporate%20office%20by%20Valeriya%20Zankovych%20via%20Shutterstock.jpg)
/The%20front%20of%20a%20Rocket%20Lab%20corporate%20office%20by%20Emagnetic%20via%20Shutterstock.jpg)
